Literature DB >> 28695920

Pharmacology: Cardiovascular effects of mirabegron.

Karl-Erik Andersson1.   

Abstract

Mesh：

Substances：

Year:  2017        PMID： 28695920     DOI： 10.1038/nrurol.2017.113

Source DB:  PubMed          Journal:  Nat Rev Urol        ISSN： 1759-4812            Impact factor:   14.432


× No keyword cloud information.
  10 in total

1.  Human atrial β(1L)-adrenoceptor but not β₃-adrenoceptor activation increases force and Ca(2+) current at physiological temperature.

Authors:  Torsten Christ; Peter Molenaar; Paul M Klenowski; Ursula Ravens; Alberto J Kaumann
Journal:  Br J Pharmacol       Date:  2011-02       Impact factor: 8.739

2.  Proarrhythmic safety of repeat doses of mirabegron in healthy subjects: a randomized, double-blind, placebo-, and active-controlled thorough QT study.

Authors:  M Malik; E M van Gelderen; J H Lee; D L Kowalski; M Yen; R Goldwater; S K Mujais; M P Schaddelee; P de Koning; A Kaibara; S S Moy; J J Keirns
Journal:  Clin Pharmacol Ther       Date:  2012-11-14       Impact factor: 6.875

3.  The risk and severity of developing symptomatic palpitations when prescribed mirabegron for overactive bladder.

Authors:  Aswini A Balachandran; Jonathan R A Duckett
Journal:  Eur J Obstet Gynecol Reprod Biol       Date:  2015-02-19       Impact factor: 2.435

Review 4.  Cardiovascular Safety of β3-adrenoceptor Agonists for the Treatment of Patients with Overactive Bladder Syndrome.

Authors:  Gian Marco Rosa; Simone Ferrero; Victor W Nitti; Adrian Wagg; Tahir Saleem; Christopher R Chapple
Journal:  Eur Urol       Date:  2015-09-28       Impact factor: 20.096

5.  The β3 -adrenoceptor agonist mirabegron increases human atrial force through β1 -adrenoceptors: an indirect mechanism?

Authors:  Weilan Mo; Martin C Michel; Xiang Wen Lee; Alberto J Kaumann; Peter Molenaar
Journal:  Br J Pharmacol       Date:  2017-07-07       Impact factor: 8.739

Review 6.  Cardiac adrenoceptors: physiological and pathophysiological relevance.

Authors:  Otto-Erich Brodde; Heike Bruck; Kirsten Leineweber
Journal:  J Pharmacol Sci       Date:  2006-04-13       Impact factor: 3.337

7.  Translational science approach for assessment of cardiovascular effects and proarrhythmogenic potential of the beta-3 adrenergic agonist mirabegron.

Authors:  Cees Korstanje; Masanori Suzuki; Koichiro Yuno; Shuichi Sato; Masashi Ukai; Marlowe J Schneidkraut; Gan X Yan
Journal:  J Pharmacol Toxicol Methods       Date:  2017-04-21       Impact factor: 1.950

8.  Pharmacokinetic properties of mirabegron, a β3-adrenoceptor agonist: results from two phase I, randomized, multiple-dose studies in healthy young and elderly men and women.

Authors:  Walter Krauwinkel; Jan van Dijk; Marloes Schaddelee; Charlotte Eltink; John Meijer; Grégory Strabach; Sjoerd van Marle; Virginie Kerbusch; Marcel van Gelderen
Journal:  Clin Ther       Date:  2012-10       Impact factor: 3.393

9.  Cardiovascular morbidity, heart rates and use of antimuscarinics in patients with overactive bladder.

Authors:  Karl-Erik Andersson; Chaitanya Sarawate; Kristijan H Kahler; Elizabeth L Stanley; Amit S Kulkarni
Journal:  BJU Int       Date:  2009-11-17       Impact factor: 5.588

10.  beta3-adrenergic receptor activation increases human atrial tissue contractility and stimulates the L-type Ca2+ current.

Authors:  V Arvydas Skeberdis; Vida Gendviliene; Danguole Zablockaite; Rimantas Treinys; Regina Macianskiene; Andrius Bogdelis; Jonas Jurevicius; Rodolphe Fischmeister
Journal:  J Clin Invest       Date:  2008-09       Impact factor: 14.808
  10 in total
  1 in total

1.  Beneficial Metabolic Effects of Mirabegron In Vitro and in High-Fat Diet-Induced Obese Mice.

Authors:  Lei Hao; Sheyenne Scott; Mehrnaz Abbasi; Yujiao Zu; Md Shahjalal Hossain Khan; Yang Yang; Dayong Wu; Ling Zhao; Shu Wang
Journal:  J Pharmacol Exp Ther       Date:  2019-04-02       Impact factor: 4.030
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.